Daewon Pharmaceutical Co. Ltd. (003220) — Cash Flow Quality Index
Daewon Pharmaceutical Co. Ltd. (003220) has a Cash Flow Quality Index of 3.80x as of March 2026. Operating cash flow of ₩9.21 Billion exceeds net income of ₩2.42 Billion, indicating high earnings quality where cash backs reported profits. See 003220 free cash flow to operating cash ratio to measure how efficiently the company converts operating cash flow to free cash.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
Daewon Pharmaceutical Co. Ltd. Cash Flow Quality Index (2011–2024)
Historical Cash Flow Quality Index for Daewon Pharmaceutical Co. Ltd. across 14 annual periods. Values consistently above 1.0x indicate high-quality earnings. Explore Daewon Pharmaceutical Co. Ltd. cash flow to debt ratio to assess how comfortably operating cash covers total debt obligations.
Annual Cash Flow Quality Index for Daewon Pharmaceutical Co. Ltd. (2011–2024)
Year-by-year earnings quality comparison for Daewon Pharmaceutical Co. Ltd.. For the full cash flow conversion analysis, see 003220 cash flow metrics.
| Year | Quality Index | Operating CF (KRW) | Net Income | YoY Change |
|---|---|---|---|---|
| 2024 | 3.21x | ₩30.04 Billion | ₩9.35 Billion | ▲ +48.5% |
| 2023 | 2.16x | ₩51.73 Billion | ₩23.92 Billion | ▲ +103.1% |
| 2022 | 1.07x | ₩33.33 Billion | ₩31.28 Billion | ▼ -68.4% |
| 2021 | 3.37x | ₩22.41 Billion | ₩6.65 Billion | ▲ +151.3% |
| 2020 | 1.34x | ₩24.95 Billion | ₩18.62 Billion | ▲ +18.1% |
| 2019 | 1.13x | ₩30.97 Billion | ₩27.29 Billion | ▼ -32.7% |
| 2018 | 1.69x | ₩40.03 Billion | ₩23.74 Billion | ▲ +324.6% |
| 2017 | 0.40x | ₩4.27 Billion | ₩10.74 Billion | ▼ -61.3% |
| 2016 | 1.03x | ₩20.79 Billion | ₩20.24 Billion | ▼ -29.6% |
| 2015 | 1.46x | ₩25.82 Billion | ₩17.69 Billion | ▲ +31.5% |
| 2014 | 1.11x | ₩17.45 Billion | ₩15.73 Billion | ▲ +10.9% |
| 2013 | 1.00x | ₩12.32 Billion | ₩12.32 Billion | ▼ -30.5% |
| 2012 | 1.44x | ₩13.83 Billion | ₩9.61 Billion | ▼ -24.3% |
| 2011 | 1.90x | ₩17.93 Billion | ₩9.44 Billion | — |